Search

Displaying results 2641 - 2650 of 10000 in total
  1. Drug

    Light green SF yellowish

    go.drugbank.com/drugs/DB11183
    Approved

    Although it has been used as a food colorant, it was discontinued from the market due to low popularity which are possibly due to low durability of the dye and increased tendency of the dye to fade. … Light green SF yellowish is a green triarylmethane dye that is used in the preparation of the staining solution which is widely used as a counterstain.

  2. Drug

    Rivastigmine

    go.drugbank.com/drugs/DB00989
    ApprovedInvestigational

    Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

    Categories: Compounds used in a research, industrial, or household settingProducts: RIVASTIGMIN ZEN 13.3MG/24H
  3. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    Ligelizumab is a humanized IgG1k monoclonal antibody targeted against immunoglobulin E (IgE). … a greater affinity for free serum IgE and an altered sensitivity to IgE conformation.

  4. Drug

    Human Rho(D) immune globulin

    go.drugbank.com/drugs/DB11597
    Approved

    It was approved by FDA as treatment for suppression of rhesus (Rh) isoimmunization or chronic immune thrombocytopenic purpura (ITP) in adults. … Rho (D) immune globulin is available as a sterile, lyophilized or liquid gamma globulin (IgG) fraction containing antibodies to the Rh0 (D) antigen (D antigen) under the name Rhophylac (IM/IV).

    Categories: anti-D (rh) immunoglobulinSynonyms: IGG, Rho (D), Anti-D immunoglobulin
  5. Drug

    Oxantel

    go.drugbank.com/drugs/DB13670
    Investigational

    Oxantel is an anthelmintic drug that targets parasitic acetylcholine receptors.[A275093, A275098]

    Mixtures: PAMOATO DE PIRANTEL/PAMOATO DE OXANTEL SUSPENSION, PAMOATO DE OXANTEL 250 MG/5ML + PAMOATO DE PIRANTEL 250 MG/5 ML SUSPENSIÓN.
  6. Drug

    Ipilimumab

    go.drugbank.com/drugs/DB06186
    ApprovedInvestigational

    [L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126] … [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

  7. Drug

    Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

    go.drugbank.com/drugs/DB10061
    ApprovedInvestigational

    four drug substances contained in each dose of vaccine. … [A253277] Several serogroups of _N. meningitidis_ - A, B, C, Y, and W-135 - known to cause meningococcal infections have been identified.

  8. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    [L45768,A258433] In the context of relapsed or refractory DLBCL, glofitamab provides an alternative treatment option for patients having failed other systemic therapies or for whom targeted therapies - … , after two or more lines of systemic therapy under accelerated approval based on response rate and durability of response.

  9. Drug

    Beclamide

    go.drugbank.com/drugs/DB09011
    Experimental

    It was studied in the 1950s for generalised tonic-clonic seizures but was not effective for absence seizures. … Beclamide (N-benzyl-B-chloropropionamide) is a no longer used drug that possesses anticonvulsant and sedative activity.

  10. Drug

    Ceruletide

    go.drugbank.com/drugs/DB00403
    Approved

    It exerts stimulatory effects on the gastric, biliary, and pancreatic secretion, as well as on certain smooth muscles. … Caerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin.